Plasminogen Activator and Fibrinogen/Fibrin Degradation Products At Conization of the Uterine Cervix

References

• Larsson G. Conization for preinvasive and early invasive carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 1983; 114(Suppl)1–40
   Google Scholar
• Wallén P, Rånby M, Bergsdorf N, Kok P. Purification and characterization of tissue plasminogen activator: on the occurrence of two different forms and their enzymatic properties. Progress in Fibrinolysis, J F. Davidson, I M. Nilsson, B Åstedt. Churchill Livingstone, Edinburgh-London-New York 1981; 16–23
   Google Scholar
• Astrup T, Sterndorff I. An activator of plasminogen in normal urine. Proc Soc Exp Biol Med 1952; 81: 675–8
   PubMed Web of Science ®Google Scholar
• Holmberg L, Kristoffersson Ann-Charlotte, Lecander Ingegerd, Wallén P, Åstedt B. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase. Scand J Clin Lab Invest 1982; 42: 347–54
   PubMedGoogle Scholar
• Åstedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976; 261: 595–7
   PubMed Web of Science ®Google Scholar
• Albrechtsen O K. The fibrinolytic activity of human tissues. Br J Haematol 1957; 3: 284–91
   PubMed Web of Science ®Google Scholar
• Astrup T. Tissue activators of plasminogen. Fed Proc 1966; 25: 42–51
   PubMedGoogle Scholar
• Glas-Greenwalt P, Beller F K., Astrup T. Comparative assays of tissue plasminogen activator in myometrium, cervix and fibromyomas of the human uterus. Am J Obstet Gynecol 1971; 110: 721–5
   PubMed Web of Science ®Google Scholar
• Mori N, Takemoto J. Studies of fibrinolytic enzymes in the field of obstetrics and gynecology, especially tissue activator. Part 2. Localization of tissue activator in the uterus. Acta Obstet Gynaecol Jpn 1969; 16: 92–6
   Google Scholar
• Todd A S. Localization of fibrinolytic activity in tissues. Br Med Bull 1964; 20: 210–2
   PubMed Web of Science ®Google Scholar
• Weiss G, Beller F K. Tissue activator of the fibrinolytic enzyme in the female reproductive system. Obstet Gynecol 1969; 34: 809–19
   Google Scholar
• Rijken D C., Wijngaards G, Zaal De Jong M, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 1979; 580: 140–53
   PubMed Web of Science ®Google Scholar
• Jensen H. Epsilon-amino-caproic acid at portio amputation. Effects on bleeding. Nord Med 1966; 75: 562–4
   Google Scholar
• Kullander M S. Lútilisation de lácide epsilon amino caproique comme hémostatique dans les conisations du col utérin. Grenoble Médico-Chirurgical 1968; 6: 505–8
   Google Scholar
• Landin L E., Weiner E. Late bleeding after conization. The effect of tranexamic acid (CyklokapronR). Opusc Med 1975; 20: 280–4
   Google Scholar
• Lundvall F, Nielsen N C. The hemostatic effect of tranexamic acid in conisatio colli uteri. Acta Obstet Gynecol Scand 1984; 63: 81–4
   Web of Science ®Google Scholar
• Rybo G, Westerberg H. The effect of tranexamic acid (AMCA) on postoperative bleeding after conization. Acta Obstet Gynecol Scand 1972; 51: 347–50
   PubMed Web of Science ®Google Scholar
• Bjerre B, Eliasson G, Linell F, Söderberg H, Sjöberg N-O. Conization as only treatment of carcinoma in situ of the uterine cervix. Am J Obstet Gynecol 1976; 125: 143–52
   PubMedGoogle Scholar
• Larsson G. Conization for cervical dysplasia and carcinoma in situ: Long term follow-up of 1013 women. Ann Chir Gynaecol 1981; 70: 79–85
   PubMedGoogle Scholar
• Ahlgren M, Ingemarsson I, Lindberg L G., Nordqvist S RB. Conization as treatment of carcinoma in situ of the uterine cervix. Obstet Gynecol 1975; 46: 135–40
   Google Scholar
• Grundsell H, Larsson G, Bekassy Z. On the role of an antifibrinolytic agent (tranexamic acid) and lateral sutures at laser conization. Obstet Gynecol
   Google Scholar
• Åstedt B, Holmberg L, Lecander Ingegerd, Thorell J. Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures. Eur J Cancer 1981; 17: 239–44
   PubMed Web of Science ®Google Scholar
• Åstedt B. No crossreaction between circulating plasminogen activator and urokinase. Thromb Res 1979; 14: 535–9
   PubMed Web of Science ®Google Scholar
• Niléhn J E. Separation and estimation of “split products” of fibrinogen and fibrin in human serum. Thromb Diath Haemorrh 1967; 18: 487–92
   PubMedGoogle Scholar
• Laurell C B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45–8
   PubMed Web of Science ®Google Scholar
• Rijken D C., Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815–30
   PubMed Web of Science ®Google Scholar
• Prentice C RM. Basis of antifibrinolytic therapy. Therapeutic considerations. J Clin Pathol 1979; 33(Suppl, 14)35–40
   Google Scholar